EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum

Han Ah Lee, Gi-Ae Kim, Won Kim

Clinical and Molecular Hepatology · 30.09.2026 · 32 (Suppl) · e2026.0367

DOI: 10.3350/cmh.2026.0367 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 30.09.2026. Verfasst von Han Ah Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fatty Liver, Liver Diseases, Alcoholic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Kyung Hee University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A paradigm shift in fatty liver disease nomenclature has introduced steatotic liver disease (SLD) as an umbrella term, encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD). These SLD subtypes exist along a dynamic continuum shaped by the synergistic interplay of metabolic dysfunction and alcohol exposure. Accumulating evidence indicates that SLD exhibits distinct outcome-based clusters reflecting heterogeneity in pathogenic drivers and clinical trajectories. Cardiometabolic clusters, most prominently observed in MASLD, are characterized by systemic metabolic dysfunction and confer increased risks of cardiovascular disease (CVD). In contrast, liver-specific clusters demonstrate progressive fibrosis and cirrhosis, hepatic decompensation, and hepatocellular carcinoma. In large-scale cohorts, CVD accounts for 40-50% of deaths in MASLD, while liver-related mortality predominates in ALD (>60%). The relative dominance of cardiometabolic versus liver-specific clusters shifts progressively across the MASLD-MetALD-ALD spectrum. While CVD remains a major driver of mortality, particularly in MASLD, hepatic outcomes increase stepwise with advancing fibrosis and greater alcohol exposure. Advanced fibrosis is the predominant shared determinant amplifying both CVD and hepatic risks across subtypes. This review synthesizes cardiovascular and hepatic outcome patterns across the MASLD-MetALD-ALD spectrum, highlighting the prognostic reorientation across the continuum, in which hepatic outcomes rise stepwise with alcohol exposure while cardiovascular risk remains an important but less subtype-differentiated burden. These findings advocate outcome-oriented risk stratification integrating noninvasive fibrosis assessment, alcohol biomarkers (phosphatidylethanol), and cardiovascular risk calculators within the cardiovascular-kidney-metabolic framework. Understanding SLD as a modifiable continuum enables individualized management to optimize multisystem outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesFatty LiverLiver Diseases, AlcoholicHumansPrognosisLiverLiver CirrhosisLiver NeoplasmsFatty Liver, AlcoholicRisk FactorsCarcinoma, Hepatocellular

Stichwörter der Autor:innen

Alcohol-associated liver diseaseCardiovascular outcomesCardiovascular-kidney-metabolic syndromeFibrosisHepatic decompensationMetabolic dysfunction and alcohol-related liver diseaseMetabolic dysfunction–associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
  • Biomedical Research Institute, Chung-Ang University Hospital, Seoul, Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. drwon1@snu.ac.kr.
  • Divisions of Gastroenterology and Hepatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea. drwon1@snu.ac.kr.

Förderung

  • Kyung Hee University

Zitieren

APA

Lee, H. A., Kim, G. A., & Kim, W. (2026). Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum. Clinical and Molecular Hepatology, 32(Suppl), e2026.0367. https://doi.org/10.3350/cmh.2026.0367

Vancouver

Lee HA, Kim GA, Kim W. Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum. Clinical and Molecular Hepatology. 2026;32(Suppl):e2026.0367. doi:10.3350/cmh.2026.0367

BibTeX
@article{Lee2026,
  author = {Lee, Han Ah and Kim, Gi-Ae and Kim, Won},
  title = {Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {Suppl},
  pages = {e2026.0367},
  doi = {10.3350/cmh.2026.0367}
}
Kostenlos starten →